1227939-82-3

Basic information

• Product Name: ABT-348
• Synonyms: ABT-348;Ilorasertib;A 968660.0;Abbott 968660;N-[4-[4-Amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-N'-(3-fluorophenyl)urea;Vilaprisan
• CAS NO: 1227939-82-3
• Molecular Formula: C25H21FN6O2S
• Molecular Weight: 488.5366432
• Mol File: 1227939-82-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ABT-348(CAS DataBase Reference)
• NIST Chemistry Reference: ABT-348(1227939-82-3)
• EPA Substance Registry System: ABT-348(1227939-82-3)

Safety Data

• Hazardous Substances Data: 1227939-82-3(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
ABT-348 is used as an anticancer agent for its ability to inhibit the proliferation and metastatic advancement of cancer cells. It targets key ATP-dependent enzymes involved in cell cycle progression, cell survival, and angiogenesis, making it a potential treatment for various types of tumors and cancers.
Used in Drug Development:
ABT-348 is used as a research compound in the development of new cancer therapies. Its ATP competitive inhibitory characteristics provide a unique approach to targeting enzymes that play a significant role in the growth and spread of cancer cells, offering a potential avenue for the creation of novel treatments.
Used in Cancer Research:
ABT-348 is used as a research tool in cancer research to better understand the mechanisms by which it disrupts the growth and spread of cancer cells. This knowledge can contribute to the development of more effective cancer treatments and a deeper understanding of the molecular underpinnings of cancer progression.

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 942947-94-6 5-bromo-4-chloro-pyridin-2-ylamine 
• 683738-44-5 2-aminopyridine-4-thiol 
• 1040377-08-9 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]ethanol 
• 1420775-77-4 1-(4-(4-amino-7-iodothieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea 
• 1227939-87-8 2-(4-(4-amino-3-(4-aminophenyl)thieno[3,2-c]pyridin-7-yl)-1H-pyrazol-1-yl)ethanol 
• 404-71-7 1-fluoro-3-isocyanatobenzene 
• 330793-01-6 (4-tert-butoxycarbonylaminophenyl)boronic acid pinacol ester 
• 832695-08-6 tert-butyl 4-(4-amino-7-iodothieno[3,2-c]pyridin-3-yl)phenylcarbamate 
• 832695-04-2 t-butyl-4-(4-aminothieno[3,2-c]pyridine-3-yl)phenylcarbamate 
• 832695-09-7 3-(4-aminophenyl)-7-iodothieno[3,2-c]pyridin-4-amine 
• 799293-85-9 3-bromo-4-amino-[3,2-c]-thienopyridine 

Relevant articles and documents

PROCESSES TO MAKE PROTEIN KINASE INHIBITORS

Processes to prepare compounds that inhibit protein kinases such as Aurora kinases and the VEGFR and PDGFR families of kinases are discussed.

Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families

In an effort to identify multi-targeted kinase inhibitors with a novel spectrum of kinase activity, a screen of Abbott proprietary KDR inhibitors against a broad panel of kinases was conducted and revealed a series of thienopyridine ureas with promising activity against the Aurora kinases. Modification of the diphenyl urea and C7 moiety of these compounds provided potent inhibitors with good pharmacokinetic profiles that were efficacious in mouse tumor models after oral dosing. Compound 2 (ABT-348) of this series is currently undergoing Phase I clinical trials in solid and hematological cancer populations.

KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE

Compounds that inhibit protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved safety profile due to low CYP3A4 inhibition, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.